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Outcome research focusing on the economics of the medical field began in the mid-1990s and has included studies about costs, 
cost effectiveness, and policies. According to the American Diabetes Association, the total estimated cost of diabetes in 2007 was 
$174 billion. The economic burden of patients with diabetes in Canada is expected to be about $12.2 billion in 2010. Recent Ko-
rean studies have analyzed the expenses associated with type 2 diabetes for patients in selected general hospitals. Type 2 diabetic 
patients without complications cost approximately 1,184,563 won (the equivalent of US $1,184) per patient for healthcare annu-
ally. In contrast, patients with microvascular disease due to diabetic complications cost up to 4.7 times that amount, and patients 
with macrovascular disease incur up to 10.7 times the annual costs for patients without diabetic complications. Diabetic compli-
cations ultimately impact the quality of life for patients and patient mortality, and are associated with higher direct medical ex-
penses for patients. To avoid increased medical costs, appropriate management techniques must be implemented to ensure time-
ly care for patients with diabetes. 
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INTRODUCTION
Diabetes is a serious problem in medical care, health care, and 
social epidemiology worldwide. The prevalence of diabetes in 
both advanced and developing countries has increased over 
the last three decades, as a direct result of increasing popula-
tion, longer life expectancy, and the spread of a Western life-
style. These factors have lead to increased incidence, higher 
prevalence rates, and higher mortality rates due to diabetes 
[1,2].
  According to the World Health Organization and the Inter-
national Diabetes Federation, an estimated 135 million patients 
had diabetes worldwide in 1995. An estimated 194 million 
people, or 5.1% of the global population between the ages of 
20 to 79 years, had diabetes in 2003 [1]. By the year 2025, 300 
million people will be affected by diabetes worldwide, an in-
crease of 120% in just 3 decades, according to estimates by 
both organizations [1]. Studies in Korea in 1972 showed that 
1.5% of the population had diabetes. According to the Korean 
National Health and Nutrition Examination Survey (2005), 
9% of males and 7.2% of females among Koreans over the age 
of 30 years had diabetes [3,4].
OUTCOME RESEARCH
Many studies in the mid-1990s focused on the economic sta-
tus of people burdened by disease, and these research efforts 
contributed to the creation, in 1998, of the International Soci-
ety for Pharmacoeconomics and Outcome Research in Europe 
[5]. Many studies have explored various aspects of diabetes, 
including the costs of diabetic care, cost control, and the appli-
cation of policies that govern care and costs [5-8]. 
  Cost-effectiveness analysis is a form of economic evaluation 
applicable only when outcomes are one-dimensional and mea-
Review
http://dx.doi.org/10.4093/dmj.2011.35.6.567
pISSN 2233-6079 · eISSN 2233-6087568
Lee KW
Diabetes Metab J 2011;35:567-570 http://e-dmj.org
sured in naturally occurring units such as changes in blood 
pressure or mortality. As compared with cost effectiveness or 
cost minimization analyses, cost utility analysis uses a form of 
economic evaluation that enables broader comparisons between 
treatments for different disease groups. Using health utilities, 
multi-dimensional health outcomes are reduced to a single in-
dex and expressed as quality adjusted life years (QALYs) and 
disability adjusted life years of healthy year equivalents. Cost 
per unit of outcome ratios can then be derived that reflect the 
costs required to obtain one QALY, which represents 1 year of 
life without complications for patients burdened by disease. 
The QALY of patients with diabetes and end stage renal dis-
ease is only 0.43 of 1 full year, which numerically represents 
the decrease in patient quality of life attributable to renal prob-
lems associated with diabetes. Cost-benefit analysis is a form 
of economic evaluation that addresses allocative efficiency 
questions. Costs and outcomes are valued in a commensurate 
unit, often money, through techniques such as contingent val-
uation [5-8].
  Economic costs of disease are classified as direct costs and 
indirect costs. Direct costs refer specifically to costs associated 
with direct medical care, hospital outpatient care (OPD), hos-
pital inpatient care (IPD), medication, and consultation. Indi-
rect medical costs include the costs of transportation for hos-
pital visits and caregiver expenses. These types of expenses in-
clude both covered services and non-covered services within 
the Korean National Health Insurance System. Indirect costs 
include loss of labor and loss of income due to premature death 
and the costs of medical devices and disposable supplies [5-8].
COSTS OF DIABETES
According to the American Diabetes Association, the total es-
timated cost of diabetes in 2007 was $174 billion, including 
$116 billion in excess medical expenditures and $58 billion in 
reduced national productivity. Medical costs attributed to dia-
betes included $27 billion for directly treating diabetes, $58 
billion for treating diabetes-related chronic complications ow-
ing to diabetes, and $31 billion for excess general medical costs. 
The largest components of the medical expenditures were IPD 
(50% of total cost), diabetes medication and supplies (12%), 
retail prescriptions to treat complications of diabetes (11%), 
and physician office visits (9%). People diagnosed with diabe-
tes incur average expenditures of $11,744 per year, of which 
$6,649 is attributable to diabetes, and have medical expendi-
tures that are 2 to 3 times the expected expenditures in the ab-
sence of diabetes [9].
  The economic burden of diabetes in Canada is expected to 
be about $12.2 billion in 2010, as measured in inflation-adjust-
ed 2005 dollars. This is an increase of $5.9 billion or nearly 
double compared with the level in 2000. The cost of the disease 
is expected to rise by another $4.7 billion by 2020. Direct costs 
of diabetes now account for about 3.5% of public healthcare 
spending in Canada [10].
  Many studies have shown that the presence of complications 
has a substantial impact on the costs of managing patients with 
type 2 diabetes [11-13]. In Europe, the Cost of Diabetes in Eu-
rope–Type 2 Diabetes (CODE-2) study, which was conducted 
with 7,000 patients from 8 different European countries, re-
ported that the number of diabetic patients with microvascu-
lar disease or macrovascular disease was 1.7 times or 2 times 
the number of non-diabetic patients with these diseases, re-
spectively, and in individuals with both microvascular and 
macrovascular complications, the total cost of management 
was increased 3.5 fold [11]. The CODE-2 study estimated that 
55% of direct medical costs involving patients with diabetes 
pertain to admission. Moreover, admission costs were mainly 
related to the treatment of macrovascular complications, in-
cluding acute myocardial infarction, cerebrovascular infarc-
tion, and peripheral artery occlusive disease. Additional mon-
ey was spent on diagnostic and treatment procedures. When 
we consider this study, which did not take into account a po-
tential confounding factor, the year in which the complication 
occurred, we expect to find more pronounced differences in 
the direct medical costs of the diabetic treatment incurred by 
diabetic complications [14,15]. 
  In the CODE-2 study, the prevalence of retinopathy was 
20%, whereas the reported incidence of both photocoagula-
tion and vitrectomy was 2%. These findings suggest that the 
potential for cost savings exists in preventive measures and 
early retinal screening programs [16].
  According to the Korean Diabetes Association, the total es-
timated cost of diabetes for adults in 2003 was $11.7 billion, 
representing 19.1% of the total medical costs for adults [17]. 
People diagnosed with diabetes have medical expenditures 
that are 3 times the expenditures in the absence of diabetes 
[17].
  The economic burden of diabetes in Korea has been stud-
ied, and Korea has the most current reports of disease costs for 
patients with diabetes [18-20]. Fig. 1 shows that the average 569
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annual medical costs per patient in Korea were 6,994,415 won 
(US $6,994) during 2005 [19]. The annual medical costs per 
patient with microvascular disease and macrovascular disease 
were 5,546,521 won (US $5,547) and 12,631,592 won (US 
$12,632), respectively. The annual medical costs per patient 
with both types of vascular complications were 10,477,356 won 
(US $10,477). The annual medical costs per patient with mi-
crovascular disease, macrovascular disease, or both were 4.7, 
10.7, or 8.8 times the annual medical costs per patient without 
complications (1,184,563 won, or US $1,185).
  Among patients with complications, the costs for OPD and 
medications were moderately increased to 1.6 to 4.8 times the 
costs for patients without complications. In contrast, IPD costs 
were increased approximately 18.9-fold for microvascular dis-
ease and 61- to 78.9-fold for macrovascular disease. In Korea, 
as in other countries where cost analyses have been conduct-
ed, patients with diabetic complications tend to have higher 
costs than patients without complications. Higher costs due to 
macrovascular complications are particularly prominent for 
patients in Korea, according to current studies [18-20].
  For patients without diabetic complications, the total cost of 
the disease comprises OPD and medication costs. In contrast, 
the total cost of the disease also includes hospital admissions 
for patients with complications. Among patients admitted to 
hospitals with macrovascular disease, 65% to 70% of their to-
tal expenditures result from admission costs. After the analysis 
of covariance in this study was adjusted for age and gender, 
medical costs were found to increase according to the pres-
ence of complications, independent of age and gender (P<
0.001) [19].
  According to this study, the diabetic complications costing 
patients the highest annual amounts are nephropathy with 
end stage renal disease and kidney transplantation, at costs of 
24,871,318 won (US $24,871) and 27,361,088 won (US $27, 
361), respectively. The next highest costs are due to coronary 
artery disease with percutaneous transluminal coronary an-
gioplasty or coronary artery bypass graft (14,679,647 won, or 
US $14,680) and diabetic foot amputation (13,960,314 won, or 
US $13,960). The costs for diabetic patients with non-prolifer-
ative retinopathy are 3 times the costs for patients without 
complications, and the costs for patients with proliferative ret-
inopathy who receive surgery are up to 6.1 times the costs for 
patients without complications. The costs for diabetic nephrop-
athy vary based on the stage of nephropathy. For diabetic pa-
tients who develop microalbuminuria or proteinuria, the costs 
are 1.3 or 2.4 times the costs for diabetic patients without com-
plications. Diabetic patients who must receive hemodialysis or 
kidney transplantation incur costs that are 21 or 23.1 times the 
costs for diabetic patients without complications. Similarly, 
the costs for diabetic patients with coronary artery disease, 
stroke, or coronary artery obstructive disease with percutane-
ous transluminal coronary angioplasty or coronary artery by-
pass graft are 5.2, 5.3, or 12.4 times the costs for diabetic pa-
tients without complications, and the costs due to foot ampu-
tation are 11.8-fold [19].
CONCLUSION
Complications affect the quality of life and mortality of patients 
with diabetes and are associated with higher direct medical 
costs. Accordingly, to avoid increased medical costs, appropri-
ate management techniques must be implemented to ensure 
timely care for patients with diabetes. As outlined in medical 
care policies, adequate control of blood sugar, blood pressure, 
and cholesterol in conjunction with early detection of compli-
cations through appropriate screening are critical. 
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